Shozo Furumoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shozo Furumoto has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Nobuyuki Okamura
Tohoku Medical and Pharmaceutical University, Sendai Japan
14 shared publications - Kazuhiko Yanai
Dept Pharmacol Tohoku Univ Grad Sch Med
13 shared publications - Yukitsuka Kudo
Innovation of New Biomedical Engineering Center, Tohoku University, Sendai, Japan
8 shared publications Ren Iwata
Cyclotron and Radioisotope Center (CYRIC), Tohoku University, Sendai, 980-8578, Japan
7 shared publicationsRyuichi Harada
5 shared publicationsYoichi Ishikawa
Cyclotron and Radioisotope Center (CYRIC), Tohoku University, Sendai, 980-8578, Japan
5 shared publications
Latest Publications
- 20 January 2024
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 457, 122892
Amyloid accumulation in cases of suspected comorbid cerebral amyloid angiopathy and isolated cortical venous thrombosis
- 20 January 2024
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 457, 122892
Amyloid accumulation in cases of suspected comorbid cerebral amyloid angiopathy and isolated cortical venous thrombosis
- 1 March 2016
- Vol. 74 (3) , 404-9
[Tau imaging].
Several promising tau imaging probes have been developed by Tohoku University ([18F]THK series), National Institute of Radiological Sciences([11C]PBB3), Eli Lilly ([18F]T807), and Hoffman-La Roche ([18F]R06958948). In this paper we discussed some of the criteria required for the tau imaging probe in Alzheimer's disease. It will be certain that tau imaging plays an important role in an accurate diagnosis and as companion diagnostics.
- 1 March 2016
- Vol. 74 (3) , 404-9
[Tau imaging].
Several promising tau imaging probes have been developed by Tohoku University ([18F]THK series), National Institute of Radiological Sciences([11C]PBB3), Eli Lilly ([18F]T807), and Hoffman-La Roche ([18F]R06958948). In this paper we discussed some of the criteria required for the tau imaging probe in Alzheimer's disease. It will be certain that tau imaging plays an important role in an accurate diagnosis and as companion diagnostics.
- 10 February 2016
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 59 (3) , 117-123
Radiosynthesis and preliminary biological evaluation of a new 18F‐labeled triethylene glycol derivative of triphenylphosphonium
Delocalized lipophilic cations such as [18F]fluorobenzyltriphenylphosphonium ([18F]FBnTP) can accumulate in mitochondria and have been used in myocardial perfusion imaging (MPI). In this study, we established a simplified method for [18F]FBnTP synthesis using triphenylphosphine hydrobromide (PPh3•HBr) without preparing an intermediate that contains benzyl bromide structure. Applying this new method, we synthesized and evaluated a novel 18F‐labeled PEGylated BnTP derivative ([18F]FPEGBnTP). In vitro cellular uptake study demonstrated that [18F]FPEGBnTP accumulated in cells in proportion to the relative intensity of mitochondrial membrane potential. Biodistribution study revealed that the heart : liver uptake ratio of [18F]FPEGBnTP (4.00 at 60 min) was superior to that of [18F]FBnTP (1.50 at 60 min). However, [18F]FPEGBnTP showed slow blood clearance and high radioactivity uptake in bone at 120‐min post‐injection. These results imply the possibility of [18F]FPEGBnTP being used as a MPI agent. However, there is a need of further structural optimization and flow‐dependent uptake study.
- 10 February 2016
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 59 (3) , 117-123
Radiosynthesis and preliminary biological evaluation of a new 18F‐labeled triethylene glycol derivative of triphenylphosphonium
Delocalized lipophilic cations such as [18F]fluorobenzyltriphenylphosphonium ([18F]FBnTP) can accumulate in mitochondria and have been used in myocardial perfusion imaging (MPI). In this study, we established a simplified method for [18F]FBnTP synthesis using triphenylphosphine hydrobromide (PPh3•HBr) without preparing an intermediate that contains benzyl bromide structure. Applying this new method, we synthesized and evaluated a novel 18F‐labeled PEGylated BnTP derivative ([18F]FPEGBnTP). In vitro cellular uptake study demonstrated that [18F]FPEGBnTP accumulated in cells in proportion to the relative intensity of mitochondrial membrane potential. Biodistribution study revealed that the heart : liver uptake ratio of [18F]FPEGBnTP (4.00 at 60 min) was superior to that of [18F]FBnTP (1.50 at 60 min). However, [18F]FPEGBnTP showed slow blood clearance and high radioactivity uptake in bone at 120‐min post‐injection. These results imply the possibility of [18F]FPEGBnTP being used as a MPI agent. However, there is a need of further structural optimization and flow‐dependent uptake study.
- Open Access
- 6 January 2016
- Published by MDPI AG in Biomolecules
- Vol. 6 (1) , 7
Characteristics of Tau and Its Ligands in PET Imaging
Tau deposition is one of the neuropathological hallmarks in Alzheimer’s disease as well as in other neurodegenerative disorders called tauopathies. Recent efforts to develop selective tau radiopharmaceuticals have allowed the visualization of tau deposits in vivo. In vivo tau imaging allows the assessment of the regional distribution of tau deposits in a single human subject over time for determining the pathophysiology of tau accumulation in aging and neurodegenerative conditions as well as for application in drug discovery of anti-dementia drugs as surrogate markers. However, tau deposits show complicated characteristics because of different isoform composition, histopathology, and ultrastructure in various neurodegenerative conditions. In addition, since tau radiopharmaceuticals possess different chemotype classes, they may show different binding characteristics with heterogeneous tau deposits. In this review, we describe the characteristics of tau deposits and their ligands that have β-sheet binding properties, and the status of tau imaging in clinical studies.
- 6 January 2016
- Published by MDPI AG in Biomolecules
- Vol. 6 (1) , 7
Open AccessCharacteristics of Tau and Its Ligands in PET Imaging
Tau deposition is one of the neuropathological hallmarks in Alzheimer’s disease as well as in other neurodegenerative disorders called tauopathies. Recent efforts to develop selective tau radiopharmaceuticals have allowed the visualization of tau deposits in vivo. In vivo tau imaging allows the assessment of the regional distribution of tau deposits in a single human subject over time for determining the pathophysiology of tau accumulation in aging and neurodegenerative conditions as well as for application in drug discovery of anti-dementia drugs as surrogate markers. However, tau deposits show complicated characteristics because of different isoform composition, histopathology, and ultrastructure in various neurodegenerative conditions. In addition, since tau radiopharmaceuticals possess different chemotype classes, they may show different binding characteristics with heterogeneous tau deposits. In this review, we describe the characteristics of tau deposits and their ligands that have β-sheet binding properties, and the status of tau imaging in clinical studies.
- Open Access
- 23 December 2015
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 57 (4) , 608-614
Structure–Activity Relationship of 2-Arylquinolines as PET Imaging Tracers for Tau Pathology in Alzheimer Disease
Abnormal deposition of amyloid-β and hyperphosphorylated tau protein in the brain are the pathologic hallmark of Alzheimer disease (AD). Noninvasive detection of the lesions is considered an effective tool for early diagnosis and staging of AD. In the past decade, we developed 2-arylquinoline (2-AQ) derivatives as PET tau tracers. In this study, we synthesized new derivatives and evaluated their properties. Methods: Fifteen 2-AQ derivatives were labeled with 18F, and their binding to tau lesions was evaluated by autoradiography using AD brain sections. The binding affinity for the AD brain homogenates was assessed by an in vitro competitive binding assay with 18F-THK-5105. 18F-labeled derivatives were injected into mice via the tail vein, and their pharmacokinetics over the first 120 min after injection were evaluated by an ex vivo biodistribution study. Tracer metabolism analysis was also assessed in mice. Results: The average log P value was 2.80. This study revealed that 2-AQ derivatives having 18F-labeled side chains on benzene or position 7 of the quinoline showed significantly lower binding affinity for tau than 6-substituted quinoline derivatives. The 2-AQ derivatives labeled with 18F-fluoroethoxy, 18F-fluoropropoxy, and 18F-fluoro-polyethyleneglycol groups displayed slow clearance from blood or a high accumulation in bone, whereas derivatives labeled with the 18F-(3-fluoro-2-hydroxy)propoxyl group did not. 18F-THK-5151 had outstanding tau binding properties and pharmacokinetics. Furthermore, the properties of its optically pure (S)-enantiomer (THK-5351) were superior to those of the (R)-enantiomer (THK-5451), particularly in terms of its clearance from the brain and its resistance to defluorination in mice. Conclusion: The structure–activity relationship study of 2-AQ derivatives revealed the optimal structural features for tau imaging agents. On the basis of these results, 18F-THK-5351 ((S)-18F-THK-5151) was selected as a potential agent for tau imaging.
- 23 December 2015
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 57 (4) , 608-614
Open AccessStructure–Activity Relationship of 2-Arylquinolines as PET Imaging Tracers for Tau Pathology in Alzheimer Disease
Abnormal deposition of amyloid-β and hyperphosphorylated tau protein in the brain are the pathologic hallmark of Alzheimer disease (AD). Noninvasive detection of the lesions is considered an effective tool for early diagnosis and staging of AD. In the past decade, we developed 2-arylquinoline (2-AQ) derivatives as PET tau tracers. In this study, we synthesized new derivatives and evaluated their properties. Methods: Fifteen 2-AQ derivatives were labeled with 18F, and their binding to tau lesions was evaluated by autoradiography using AD brain sections. The binding affinity for the AD brain homogenates was assessed by an in vitro competitive binding assay with 18F-THK-5105. 18F-labeled derivatives were injected into mice via the tail vein, and their pharmacokinetics over the first 120 min after injection were evaluated by an ex vivo biodistribution study. Tracer metabolism analysis was also assessed in mice. Results: The average log P value was 2.80. This study revealed that 2-AQ derivatives having 18F-labeled side chains on benzene or position 7 of the quinoline showed significantly lower binding affinity for tau than 6-substituted quinoline derivatives. The 2-AQ derivatives labeled with 18F-fluoroethoxy, 18F-fluoropropoxy, and 18F-fluoro-polyethyleneglycol groups displayed slow clearance from blood or a high accumulation in bone, whereas derivatives labeled with the 18F-(3-fluoro-2-hydroxy)propoxyl group did not. 18F-THK-5151 had outstanding tau binding properties and pharmacokinetics. Furthermore, the properties of its optically pure (S)-enantiomer (THK-5351) were superior to those of the (R)-enantiomer (THK-5451), particularly in terms of its clearance from the brain and its resistance to defluorination in mice. Conclusion: The structure–activity relationship study of 2-AQ derivatives revealed the optimal structural features for tau imaging agents. On the basis of these results, 18F-THK-5351 ((S)-18F-THK-5151) was selected as a potential agent for tau imaging.
- 21 July 2015
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 18 (2) , 258-266
Preclinical Evaluation of [18F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer
Noninvasive imaging of tau and amyloid-β pathologies would facilitate diagnosis of Alzheimer’s disease (AD). Recently, we have developed [18F]THK-5105 for selective detection of tau pathology by positron emission tomography (PET). The purpose of this study was to clarify biological properties of optically pure [18F]THK-5105 enantiomers.
- 21 July 2015
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 18 (2) , 258-266
Preclinical Evaluation of [18F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer
Noninvasive imaging of tau and amyloid-β pathologies would facilitate diagnosis of Alzheimer’s disease (AD). Recently, we have developed [18F]THK-5105 for selective detection of tau pathology by positron emission tomography (PET). The purpose of this study was to clarify biological properties of optically pure [18F]THK-5105 enantiomers.
- 21 September 2014
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 14 (11) , 1-7
Tau PET Imaging in Alzheimer’s Disease
In several neurodegenerative diseases that are collectively called tauopathies, progressive accumulation of tau in the brain is closely associated with neurodegeneration and cognitive impairment. Noninvasive detection of tau protein deposits in the brain would be useful to diagnose tauopathies as well as to track and predict disease progression. Recently, several tau PET tracers including T807, THK-5117, and PBB3 have been developed and succeeded in imaging neurofibrillary pathology in vivo. For use of tau PET as a biomarker of tau pathology in Alzheimer’s disease, PET tracers should have high affinity to PHF-tau and high selectivity for tau over amyloid-β and other protein deposits. PET tau imaging enables the longitudinal assessment of the spatial pattern of tau deposition and its relation to amyloid-β pathology and neurodegeneration. This technology could also be applied to the pharmacological assessment of anti-tau therapy, thereby allowing preventive interventions.
- 21 September 2014
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 14 (11) , 1-7
Tau PET Imaging in Alzheimer’s Disease
In several neurodegenerative diseases that are collectively called tauopathies, progressive accumulation of tau in the brain is closely associated with neurodegeneration and cognitive impairment. Noninvasive detection of tau protein deposits in the brain would be useful to diagnose tauopathies as well as to track and predict disease progression. Recently, several tau PET tracers including T807, THK-5117, and PBB3 have been developed and succeeded in imaging neurofibrillary pathology in vivo. For use of tau PET as a biomarker of tau pathology in Alzheimer’s disease, PET tracers should have high affinity to PHF-tau and high selectivity for tau over amyloid-β and other protein deposits. PET tau imaging enables the longitudinal assessment of the spatial pattern of tau deposition and its relation to amyloid-β pathology and neurodegeneration. This technology could also be applied to the pharmacological assessment of anti-tau therapy, thereby allowing preventive interventions.
- Open Access
- 26 February 2014
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 6 (1) , 11
Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies
Introduction: The introduction of tau imaging agents such as 18F-THK523 offers new hope for the in vivo assessment of tau deposition in tauopathies such as Alzheimer’s disease (AD), where preliminary 18F-THK523-PET studies have demonstrated significantly higher cortical retention of 18F-THK523 in AD compared to age-matched healthy individuals. In addition to AD, tau imaging with PET may also be of value in assessing non-AD tauopathies, such as corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) and Pick’s disease (PiD). Methods: To further investigate the ability of THK523 to recognize tau lesions, we undertook immunohistochemical and fluorescence studies in serial brain sections taken from individuals with AD (n = 3), CBD (n = 2), PSP (n = 1), PiD (n = 2) and Parkinson’s disease (PD; n = 2). In addition to the neuropathological analysis, one PSP patient had undergone a 18F-THK523 PET scan 5 months before death. Results: Although THK523 labelled tau-containing lesions such as neurofibrillary tangles and neuropil threads in the hippocampus and frontal regions of AD brains, it failed to label tau-containing lesions in non-AD tauopathies. Furthermore, though THK523 faintly labelled dense-cored amyloid-β plaques in the AD frontal cortex, it failed to label α-synuclein-containing Lewy bodies in PD brain sections. Conclusion: The results of this study suggest that 18F-THK523 selectively binds to paired helical filament tau in AD brains but does not bind to tau lesions in non-AD tauopathies, or to α-synuclein in PD brains.
- 26 February 2014
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 6 (1) , 11
Open AccessAssessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies
Introduction: The introduction of tau imaging agents such as 18F-THK523 offers new hope for the in vivo assessment of tau deposition in tauopathies such as Alzheimer’s disease (AD), where preliminary 18F-THK523-PET studies have demonstrated significantly higher cortical retention of 18F-THK523 in AD compared to age-matched healthy individuals. In addition to AD, tau imaging with PET may also be of value in assessing non-AD tauopathies, such as corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) and Pick’s disease (PiD). Methods: To further investigate the ability of THK523 to recognize tau lesions, we undertook immunohistochemical and fluorescence studies in serial brain sections taken from individuals with AD (n = 3), CBD (n = 2), PSP (n = 1), PiD (n = 2) and Parkinson’s disease (PD; n = 2). In addition to the neuropathological analysis, one PSP patient had undergone a 18F-THK523 PET scan 5 months before death. Results: Although THK523 labelled tau-containing lesions such as neurofibrillary tangles and neuropil threads in the hippocampus and frontal regions of AD brains, it failed to label tau-containing lesions in non-AD tauopathies. Furthermore, though THK523 faintly labelled dense-cored amyloid-β plaques in the AD frontal cortex, it failed to label α-synuclein-containing Lewy bodies in PD brain sections. Conclusion: The results of this study suggest that 18F-THK523 selectively binds to paired helical filament tau in AD brains but does not bind to tau lesions in non-AD tauopathies, or to α-synuclein in PD brains.
- 16 October 2013
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 57 (1) , 18-24
Synthesis and preliminary evaluation of 2‐arylhydroxyquinoline derivatives for tau imaging
Alzheimer's disease (AD) is the most common cause of dementia. Senile plaques, consisting of β‐amyloid, and neurofibrillary tangles (NFTs), composed of tau protein, are representative pathological hallmarks of AD. It is believed that the accumulation of NFTs precedes the onset of clinical symptoms of AD and correlates with the progression of memory dysfunction. Thus, the use of noninvasive detection techniques including radiolabeled probes and positron emission tomography (PET) will facilitate early diagnosis or staging of AD. In this study, we synthesized and evaluated novel hydroxylated 2‐arylquinoline derivatives as tau imaging PET probes. The binding affinities of compounds for tau were evaluated by fluorescent staining of the AD hippocampal section and a competitive binding assay using [18F]THK‐523. THK‐951 showed high binding affinity for tau pathology in an AD brain section and K18Δ280K fibrils (Ki = 20.7 nM); thus, we radiosynthesized a 11C‐labeled THK‐951 and further studied its potential as a tau PET probe. The [11C]THK‐951 demonstrated excellent kinetics in a normal mouse brain (3.23% ID/g at 2 min postinjection and 0.15% ID/g at 30 min postinjection) and showed the labeling of NFTs in an AD brain section by autoradiography assay. These findings indicate the availability of [11C]THK‐951 for in vivo PET imaging of tau pathology in AD. Copyright © 2013 John Wiley & Sons, Ltd.
- 16 October 2013
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 57 (1) , 18-24
Synthesis and preliminary evaluation of 2‐arylhydroxyquinoline derivatives for tau imaging
Alzheimer's disease (AD) is the most common cause of dementia. Senile plaques, consisting of β‐amyloid, and neurofibrillary tangles (NFTs), composed of tau protein, are representative pathological hallmarks of AD. It is believed that the accumulation of NFTs precedes the onset of clinical symptoms of AD and correlates with the progression of memory dysfunction. Thus, the use of noninvasive detection techniques including radiolabeled probes and positron emission tomography (PET) will facilitate early diagnosis or staging of AD. In this study, we synthesized and evaluated novel hydroxylated 2‐arylquinoline derivatives as tau imaging PET probes. The binding affinities of compounds for tau were evaluated by fluorescent staining of the AD hippocampal section and a competitive binding assay using [18F]THK‐523. THK‐951 showed high binding affinity for tau pathology in an AD brain section and K18Δ280K fibrils (Ki = 20.7 nM); thus, we radiosynthesized a 11C‐labeled THK‐951 and further studied its potential as a tau PET probe. The [11C]THK‐951 demonstrated excellent kinetics in a normal mouse brain (3.23% ID/g at 2 min postinjection and 0.15% ID/g at 30 min postinjection) and showed the labeling of NFTs in an AD brain section by autoradiography assay. These findings indicate the availability of [11C]THK‐951 for in vivo PET imaging of tau pathology in AD. Copyright © 2013 John Wiley & Sons, Ltd.
- Open Access
- 10 July 2013
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 54 (8) , 1354-1361
In Vitro and In Vivo Characterization of 2-Deoxy-2-18F-Fluoro-d-Mannose as a Tumor-Imaging Agent for PET
2-Deoxy-2-18F-fluoro-d-mannose (18F-FDM) is an 18F-labeled mannose derivative and a stereoisomer of 18F-FDG. Our preliminary study demonstrated that 18F-FDM accumulated in tumors to the same extent as 18F-FDG, with less uptake in the brain and faster clearance from the blood. However, detailed studies on the uptake of 18F-FDM in tumors have not been conducted. We undertook this study to establish a practical method of 18F-FDM synthesis based on an 18F-nucleophilic substitution (SN2) reaction and to advance the biologic characterization of 18F-FDM for potential application as a tumor-imaging agent. Methods: We synthesized 4,6-O-benzylidene-3-O-ethoxymethyl-1-O-methyl-2-O-trifluoromethanesulfonyl-β-d-glucopyranoside as a precursor for the nucleophilic synthesis of 18F-FDM. The precursor was radiofluorinated with 18F-KF/Kryptofix222, followed by removal of the protecting groups with an acid. 18F-FDM was purified by preparative high-performance liquid chromatography and then subjected to in vitro evaluation regarding phosphorylation by hexokinase as well as uptake and metabolism in AH109A tumor cells. The in vivo properties of 18F-FDM were examined in Donryu rats bearing AH109A tumor cells by biodistribution studies and imaging with a small-animal PET system. Results: We radiosynthesized 18F-FDM in sufficient radiochemical yields (50%–68%) with excellent purities (97.6%–98.7%). 18F-FDM was phosphorylated rapidly by hexokinase, resulting in 98% conversion into 18F-FDG-6-phosphate within 30 min. Tumor cells showed significant uptake of 18F-FDM with time in vitro, and uptake was dose-dependently inhibited by d-glucose. 18F-FDM injected into tumor-bearing rats showed greater uptake in tumors (2.17 ± 0.32 percentage injected dose per gram [%ID/g]) than in the brain (1.42 ± 0.10 %ID/g) at 60 min after injection. PET studies also revealed the tumor uptake of 18F-FDM (quasi–standardized uptake value, 2.83 ± 0.22) to be the same as that of 18F-FDG (2.40 ± 0.30), but the brain uptake of 18F-FDM (1.89 ± 0.13) was ≈30% lower than that of 18F-FDG (2.63 ± 0.26). Conclusion: We prepared 18F-FDM with good radiochemical yield and purity by an SN2 reaction. We demonstrated that 18F-FDM had adequate tumor cell uptake by a metabolic trapping mechanism and can afford high-contrast tumor images with less uptake in the brain, indicating that 18F-FDM has almost the same potential as 18F-FDG for PET tumor imaging, with better advantages with regard to the imaging of brain tumors.
- 10 July 2013
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 54 (8) , 1354-1361
Open AccessIn Vitro and In Vivo Characterization of 2-Deoxy-2-18F-Fluoro-d-Mannose as a Tumor-Imaging Agent for PET
2-Deoxy-2-18F-fluoro-d-mannose (18F-FDM) is an 18F-labeled mannose derivative and a stereoisomer of 18F-FDG. Our preliminary study demonstrated that 18F-FDM accumulated in tumors to the same extent as 18F-FDG, with less uptake in the brain and faster clearance from the blood. However, detailed studies on the uptake of 18F-FDM in tumors have not been conducted. We undertook this study to establish a practical method of 18F-FDM synthesis based on an 18F-nucleophilic substitution (SN2) reaction and to advance the biologic characterization of 18F-FDM for potential application as a tumor-imaging agent. Methods: We synthesized 4,6-O-benzylidene-3-O-ethoxymethyl-1-O-methyl-2-O-trifluoromethanesulfonyl-β-d-glucopyranoside as a precursor for the nucleophilic synthesis of 18F-FDM. The precursor was radiofluorinated with 18F-KF/Kryptofix222, followed by removal of the protecting groups with an acid. 18F-FDM was purified by preparative high-performance liquid chromatography and then subjected to in vitro evaluation regarding phosphorylation by hexokinase as well as uptake and metabolism in AH109A tumor cells. The in vivo properties of 18F-FDM were examined in Donryu rats bearing AH109A tumor cells by biodistribution studies and imaging with a small-animal PET system. Results: We radiosynthesized 18F-FDM in sufficient radiochemical yields (50%–68%) with excellent purities (97.6%–98.7%). 18F-FDM was phosphorylated rapidly by hexokinase, resulting in 98% conversion into 18F-FDG-6-phosphate within 30 min. Tumor cells showed significant uptake of 18F-FDM with time in vitro, and uptake was dose-dependently inhibited by d-glucose. 18F-FDM injected into tumor-bearing rats showed greater uptake in tumors (2.17 ± 0.32 percentage injected dose per gram [%ID/g]) than in the brain (1.42 ± 0.10 %ID/g) at 60 min after injection. PET studies also revealed the tumor uptake of 18F-FDM (quasi–standardized uptake value, 2.83 ± 0.22) to be the same as that of 18F-FDG (2.40 ± 0.30), but the brain uptake of 18F-FDM (1.89 ± 0.13) was ≈30% lower than that of 18F-FDG (2.63 ± 0.26). Conclusion: We prepared 18F-FDM with good radiochemical yield and purity by an SN2 reaction. We demonstrated that 18F-FDM had adequate tumor cell uptake by a metabolic trapping mechanism and can afford high-contrast tumor images with less uptake in the brain, indicating that 18F-FDM has almost the same potential as 18F-FDG for PET tumor imaging, with better advantages with regard to the imaging of brain tumors.